Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 511,332 shares of the biopharmaceutical company's stock after selling 79,159 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Gilead Sciences were worth $47,232,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. HHM Wealth Advisors LLC raised its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC boosted its position in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Trading Down 3.1 %

Shares of Gilead Sciences stock traded down $3.29 during mid-day trading on Thursday, hitting $103.25. The stock had a trading volume of 7,268,702 shares, compared to its average volume of 7,522,821. The firm has a 50-day moving average of $108.85 and a two-hundred day moving average of $98.70. The firm has a market cap of $128.56 billion, a P/E ratio of 279.05, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the business posted ($1.32) earnings per share. The firm's revenue for the quarter was down .3% compared to the same quarter last year. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.06%. Gilead Sciences's payout ratio is currently 66.53%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 302,785 shares of company stock valued at $30,540,875 over the last 90 days. 0.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on GILD shares. Bank of America lifted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Piper Sandler boosted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $109.43.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.